European Neuroendocrine Tumor Society (<scp>ENETS</scp>) 2023 guidance paper for digestive neuroendocrine carcinoma
-
- Halfdan Sorbye
- Department of Oncology, Haukeland University Hospital and Department of Clinical Science University of Bergen Bergen Norway
-
- Enrique Grande
- Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain
-
- Marianne Pavel
- Department of Medicine 1 Friedrich‐Alexander University Erlangen‐Nürnberg Erlangen Germany
-
- Margot Tesselaar
- Department of Gastrointestinal Oncology Netherlands Cancer Institute Amsterdam The Netherlands
-
- Nicola Fazio
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors European Institute of Oncology, IEO, IRCCS Milan Italy
-
- Nicholas Simon Reed
- Department of Clinical Oncology Beatson Oncology Center Glasgow UK
-
- Ulrich Knigge
- Departments of Surgery and Clinical Endocrinology ENETS Center of Excellence, Copenhagen University Hospital Rigshospitalet, Copenhagen Denmark
-
- Emanuel Christ
- Department of Endocrinology Diabetes and Metabolism, ENETS Center of Excellence, University Hospital of Basel Basel Switzerland
-
- Valentina Ambrosini
- Nuclear Medicine Alma Mater Studiorum, University of Bologna Bologna Italy
-
- Anne Couvelard
- Department of Pathology AP‐HP Bichat Hospital, Université Paris Cité Paris France
-
- Eva Tiensuu Janson
- Department of Medical Sciences, Endocrine Oncology Uppsala University Uppsala Sweden
説明
<jats:title>Abstract</jats:title><jats:p>This ENETS guidance paper, developed by a multidisciplinary working group, provides up‐to‐date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based on recent developments and study results. These recommendations aim to pave the road for more standardized care for our patients resulting in improved outcomes. Prognosis is generally poor for digestive NEC, most are advanced at diagnosis and median survival in metastatic disease is 11–12 months. Surgery can be of benefit for localized disease after extensive preoperative imaging. Carboplatin in combination with etoposide is recommended as first‐line treatment for metastatic disease. Irinotecan with fluoropyrimidines has the best evidence as second‐line treatment. Immunotherapy plays a minor role in biomarker‐unselected patients. Molecular profiling if available is encouraged to identify new targets. More prospective clinical trials are highly needed to fulfil the unmet needs in this field, especially on new predictive and prognostic biomarkers and to improve survival of patients with advanced disease.</jats:p>
収録刊行物
-
- Journal of Neuroendocrinology
-
Journal of Neuroendocrinology 35 (3), 2023-03
Wiley
